Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
AssigneeCardioVascular BioTherapeutics, Inc.
InventorThomas J. Stegmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed.
Claims17
A method for increasing cardiac efficiency of a heart having an ischemic myocardial region in a human subject, comprising the steps of:
- (a) preparing a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 (FGF-1);
- (b) injecting an amount of said pharmaceutical composition into the ischemic region of the myocardium, said amount being sufficient to induce local neoangiogenesis;
- and
- (c) evaluating at least one clinical index of cardiac function to confirm that cardiac efficiency has increased.
Dependencies are inferred from the claim text.